215 related articles for article (PubMed ID: 30840273)
41. MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4.
Ren W; Wang X; Gao L; Li S; Yan X; Zhang J; Huang C; Zhang Y; Zhi K
Mol Cell Biochem; 2014 May; 390(1-2):253-62. PubMed ID: 24609942
[TBL] [Abstract][Full Text] [Related]
42. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
Zhou X; Jin W; Jia H; Yan J; Zhang G
J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
[TBL] [Abstract][Full Text] [Related]
43. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
44. TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.
Lin Z; Song D; Wei H; Yang X; Liu T; Yan W; Xiao J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):239-46. PubMed ID: 26276504
[TBL] [Abstract][Full Text] [Related]
45. miR-145 Regulates the sensitivity of esophageal squamous cell carcinoma cells to 5-FU via targeting REV3L.
Chen Q; Hou J; Wu Z; Zhao J; Ma D
Pathol Res Pract; 2019 Jul; 215(7):152427. PubMed ID: 31072625
[TBL] [Abstract][Full Text] [Related]
46. A Feedback Loop between MicroRNA 155 (miR-155), Programmed Cell Death 4, and Activation Protein 1 Modulates the Expression of miR-155 and Tumorigenesis in Tongue Cancer.
Zargar S; Tomar V; Shyamsundar V; Vijayalakshmi R; Somasundaram K; Karunagaran D
Mol Cell Biol; 2019 Mar; 39(6):. PubMed ID: 30617160
[TBL] [Abstract][Full Text] [Related]
47. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
48. The interaction between PDCD4 and YB1 is critical for cervical cancer stemness and cisplatin resistance.
Liu D; Ke J; Liu Y; Rao H; Tang Z; Liu Y; Zhang Z; You L; Luo X; Sun Z; He Z; Li F; Qiu Z; Hu J; Mbadhi MN; Tang J; Wu F; Li S
Mol Carcinog; 2021 Dec; 60(12):813-825. PubMed ID: 34499772
[TBL] [Abstract][Full Text] [Related]
49. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
Sun FD; Wang PC; Luan RL; Zou SH; Du X
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
[TBL] [Abstract][Full Text] [Related]
51. miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Luan BH; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Nov; 71(11):640-643. PubMed ID: 29441968
[TBL] [Abstract][Full Text] [Related]
52. miR-512-3p Overcomes Resistance to Cisplatin in Retinoblastoma by Promoting Apoptosis Induced by Endoplasmic Reticulum Stress.
Kong M; Han Y; Zhao Y; Zhang H
Med Sci Monit; 2020 Jul; 26():e923817. PubMed ID: 32641679
[TBL] [Abstract][Full Text] [Related]
53. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
54. A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance.
Wu Y; Xiao Y; Ding X; Zhuo Y; Ren P; Zhou C; Zhou J
PLoS One; 2011; 6(12):e29043. PubMed ID: 22194984
[TBL] [Abstract][Full Text] [Related]
55. Mechanism of autophagy regulating chemoresistance in esophageal cancer cells.
Fang F; Li Y; Chang L
Exp Mol Pathol; 2020 Dec; 117():104564. PubMed ID: 33137292
[TBL] [Abstract][Full Text] [Related]
56. lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis.
Hu M; Zhang Q; Tian XH; Wang JL; Niu YX; Li G
Mol Carcinog; 2019 Dec; 58(12):2207-2217. PubMed ID: 31544294
[TBL] [Abstract][Full Text] [Related]
57. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
58. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions.
Cappellesso R; Tinazzi A; Giurici T; Simonato F; Guzzardo V; Ventura L; Crescenzi M; Chiarelli S; Fassina A
Cancer Cytopathol; 2014 Sep; 122(9):685-93. PubMed ID: 24888238
[TBL] [Abstract][Full Text] [Related]
59. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma.
Li X; Xin S; He Z; Che X; Wang J; Xiao X; Chen J; Song X
Cell Physiol Biochem; 2014; 33(6):1631-42. PubMed ID: 24902663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
